Type I Receptor Tyrosine Kinases as Targets for Therapy in Breast Cancer

被引：26

作者：

Baselga, Jose ^{[1
]}

Mendelsohn, John ^{[2
]}

机构：

[1] Hosp Gen Univ Vall DHebron, Barcelona 08035, Spain

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA | 1997年 / 2卷 / 02期

基金：

美国国家卫生研究院;

关键词：

Tyrosine kinase receptors; monoclonal antibodies; breast cancer; tyrosine kinase inhibitors; epidermal growth factor receptor; HER2/neu; erbB2;

D O I：

10.1023/A:1026355831693

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Breast carcinomas express high levels of type I tyrosine kinase receptors and their ligands. For these reason therapies directed at these receptors have the potential to be useful anti-cancer agents. A series of monoclonal antibodies (MAbs)(3) directed against the EGF receptor and the closely related erbB2/HER2/neu receptor are currently under evaluation. These MAbs have shown promising preclinical activity and "chimeric" and "humanized" MAbs have been produced in order to obviate the problem of host immune reactions. These antibodies are currently being tested in clinical trials either alone or in combination with chemotherapeutic agents. Clinical activity with anti-HER2/neu MAbs has been documented in patients with advanced breast cancer. In addition, compounds that inhibit receptor tyrosine kinases have shown significant preclinical activity and are potential candidates for clinical testing.

引用

页码：165 / 174

页数：10

共 57 条

[1] GROWTH-FACTORS AND CANCER [J].